• Citer

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

par Loibl, Sibylle;Von Minckwitz, Gunter;Schneeweiss, Andreas;Paepke, Stefan;Lehmann, Annika;Rezai, Mahdi;Zahm, Dirk DM;Sinn, Peter;Khandan, Fariba;Eidtmann, Holger;Dohnal, Karel;Heinrichs, Clemens;Huober, Jens;Pfitzner, Berit BM;Fasching, Peter A;Andre, Fabrice;Lindner, Judith JL;Sotiriou, Christos ;Dykgers, August;Guo, Sanxing;Gade, Stephan;Nekljudova, Valentina;Loi, Sherene ;Untch, Michael;Denkert, Carsten
Référence Journal of clinical oncology, 32, 29, page (3212-3220)
Publication Publié, 2014-10

Article révisé par les pairs

• Détails
• Contenu

Titre:	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Auteur:	Loibl, Sibylle; Von Minckwitz, Gunter; Schneeweiss, Andreas; Paepke, Stefan; Lehmann, Annika; Rezai, Mahdi; Zahm, Dirk DM; Sinn, Peter; Khandan, Fariba; Eidtmann, Holger; Dohnal, Karel; Heinrichs, Clemens; Huober, Jens; Pfitzner, Berit BM; Fasching, Peter A; Andre, Fabrice; Lindner, Judith JL; Sotiriou, Christos; Dykgers, August; Guo, Sanxing; Gade, Stephan; Nekljudova, Valentina; Loi, Sherene; Untch, Michael; Denkert, Carsten
Informations sur la publication:	Journal of clinical oncology, 32, 29, page (3212-3220)
Statut de publication:	Publié, 2014-10
Sujet CREF:	Cancérologie
	Médecine pathologie humaine
	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Anthracyclines -- administration & dosage
	Antibodies, Monoclonal, Humanized -- administration & dosage
	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Breast Neoplasms -- drug therapy -- genetics -- pathology
	Exons
	Female
	Genotype
	Humans
	Middle Aged
	Mutation
	Neoadjuvant Therapy
	Phosphatidylinositol 3-Kinases -- genetics
	Quinazolines -- administration & dosage
	Randomized Controlled Trials as Topic
	Receptor, ErbB-2 -- antagonists & inhibitors -- genetics
	Taxoids -- administration & dosage
	Treatment Outcome
	Tumor Markers, Biological -- analysis
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2014.55.7876
	info:pii/JCO.2014.55.7876
	info:pmid/25199759